A Phase 3, Multicenter, Open-Label, 12-Month Extension Safety and Tolerability Trial of Lisdexamfetamine Dimesylate in Adults With Binge Eating Disorder

BACKGROUND: A 12-month, open-label extension study assessed the long-term safety and tolerability of lisdexamfetamine dimesylate (LDX) in adults with binge eating disorder (BED). METHODS: Adults (aged 18–55 y) with BED who completed 1 of 3 antecedent studies were enrolled in a 52-week, open-label ex...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :J Clin Psychopharmacol
Главные авторы: Gasior, Maria, Hudson, James, Quintero, Javier, Ferreira-Cornwell, M. Celeste, Radewonuk, Jana, McElroy, Susan L.
Формат: Artigo
Язык:Inglês
Опубликовано: Lippincott Williams & Wilkins 2017
Предметы:
Original Contributions
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5400413/
https://ncbi.nlm.nih.gov/pubmed/28383364
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JCP.0000000000000702
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы